Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Computer-aided colonoscopy minimizes adenoma miss rate

01 Nov 2020
Although the prevalence for perforation during colonoscopy is small, patients should not neglect the underlying medical risks.

Computer-aided detection (CADe) systems help reduce adenoma miss rate during colonoscopy, a new study has found.

Researchers conducted a prospective study of patients referred for diagnostic or surveillance colonoscopies. Participants were randomly assigned to receive routine (n=185; mean age, 47.19±10.38 years) or CADe-assisted (n=184; mean age, 47.72±10.82 years) colonoscopies. All patients also underwent a second-pass colonoscopy using the opposite method.

Adenoma miss rate (AMR), the number of adenomas detected in the second-pass round divided by the total number of adenomas, was the primary outcome.

The AMR was significantly lower in the CADe procedures than in the routine white light colonoscopies (13.89 percent vs 40.00 percent; p<0.0001), as was the polyp miss rate (12.98 percent vs 45.90 percent; p<0.0001).

The overall adenoma (ADR) and polyp (PDR) detection rates, as well as adenoma (APC) and polyp (PPC) per colonoscopy, did not differ between patients who underwent either CADe or routine colonoscopy during the first-pass round. However, the PDR (p=0.001), APC (p<0.001), and PPC (p<0.001) were all significantly better when CADe colonoscopy was performed for the first-pass.

Similarly, CADe colonoscopy for the second pass yielded significantly better PDR (p<0.001), APC (p=0.001), and PPC (p<0.001) values, as well as ADR (p=0.043).

On the other hand, CADe colonoscopy consistently detected false polyps (n=67), which were features continuously traced by the CADe system but ultimately deemed as not polyps by the endoscopists. There were no missed polyps.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.